SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced it will highlight the Company's latest disruptive spine technology at the North American Spine Society (NASS) Annual Meeting held September 26-29, 2018 in Los Angeles, California, at the Los Angeles Convention Center.
"Now more than ever, NuVasive is expanding its portfolio with innovative launches covering spine's leading procedures, materials and systems," said Gregory T. Lucier, chairman and chief executive officer of NuVasive. "NuVasive is fully committed to furthering its R&D investment and bringing disruptive technology to market to meet the needs of our surgeon partners to provide better and more predictable outcomes for patients."
At the annual meeting, NuVasive will highlight its commitment in developing spine precision surgery advancements in key focus areas:
- Surgical Intelligence™ is an ecosystem of integrated, modular technologies to deliver safer, faster and smarter surgery. A key part of this ecosystem is LessRay®, a stand-alone proprietary technology that enhances low-dose, low-radiation fluoroscopy (or x-ray) images to have similar diagnostic capabilities as conventional full-dose fluoroscopy images. With the evolution of Surgical Intelligence, LessRay will integrate into the Pulse™ surgical automation platform, a first-of-its-kind integrated spine system addressing a broad range of clinical challenges, with enhanced utility and intuitive workflow. This platform introduces 2D- and 3D-navigation and smart imaging capabilities along with the Company's leading neuromonitoring, NuvaMap® O.R. surgical planning, radiation reduction and patient-specific rod-bending technologies. Both systems will be available for live demonstrations at the meeting.
- Lateral Single-Position Solutions are intended to decrease the amount of time a patient is under anesthesia and increase operating room efficiency by reducing the need for patient repositioning. This is built on the foundation of the Company's XLIF® procedure and is supported by extensive clinical evidence with more than 400 peer-reviewed, XLIF-specific publications. NuVasive's proprietary instrumentation and fixation expand the benefits of lateral surgery to more spinal levels from T6-S1, compared to traditional lateral procedures, by providing direct access to the L5-S1 level from a lateral position.
- Advanced Materials Science™ (AMS) Interbody Portfolio is designed to deliver enhanced osseointegration and biomechanics through innovative implant design and superior surface, structure and imaging characteristics. The Company's recently launched TLX® 20 degree expandable spinal interbody implant with a first-of-its-kind oblique profile designed for transforaminal lumbar interbody fusion (TLIF) procedures will be on display, and demonstrates the Company's commitment for further development of a full suite of expandable cage technologies. NuVasive is the only company to offer four specific materials for spinal interbodies: traditional PEEK (polyetheretherketone), propriety porous PEEK, titanium and 3D-printed porous titanium.
- Intraoperative Neuromonitoring (IONM)
For the first time, the NASS Annual Meeting will include an IONM symposium where surgeons can learn more about the utility, evidence and value of neuromonitoring in spine surgery, along with moderated abstract presentations. NuVasive's clinical services division is the nation's largest provider of outsourced IONM services, and the Company will demonstrate its neuromonitoring capabilities through its Pulse platform.
NuVasive 2018 NASS Annual Meeting Participation Details
NuVasive will showcase its innovation in Booth #2301 at the NASS Annual Meeting, as well as host several clinical workshops and participate in numerous podium presentations demonstrating the Company's commitment to high-quality studies to advance the full application of its spinal solutions.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.